AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15855581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2532
Study 11795350 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (selective estrogen receptor modulator)
Number of subjects: 0
Study 11795350 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 0
Study 9018407 — intervention group
Group type: EXPERIMENTAL
Intervention: Water‐Del (metered: 200 ml water every 15 min)
Number of subjects: 10
Study 9018407 — intervention group
Group type: COMPARATOR
Intervention: ad libitum every 15 min (ad‐lib‐15)
Number of subjects: 10
Study 9018407 — intervention group
Group type: COMPARATOR
Intervention: ad libitum (ad‐lib)
Number of subjects: 10
Study 7943678 — intervention group
Group type: EXPERIMENTAL
Intervention: B-MAST questionnaire for detecting alcoholism
Number of subjects: 0
Study 3086927 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational letter
Number of subjects: 277
Study 3086927 — intervention group
Group type: COMPARATOR
Intervention: No motivational letter (Control)
Number of subjects: 277
Study 30111304 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation (Radiofrequency ablation (RFA) or Microwave ablation (MWA))
Number of subjects: 618
Study 30111304 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 618
Study 30111304 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation (RFA or MWA)
Number of subjects: 618
Study 24919587 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program + phototherapy
Number of subjects: 0
Study 24919587 — intervention group
Group type: COMPARATOR
Intervention: Exercise program + placebo phototherapy
Number of subjects: 0
Study 24919587 — intervention group
Group type: COMPARATOR
Intervention: Exercise program
Number of subjects: 0
Study 23123065 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐trimethylammonium ethyl methacrylate chloride (T) and sulfobetaine methacrylate (S) coatings at 30% or 35% concentration
Number of subjects: 0
Study 23123065 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐hydroxypropyl methacrylate (HP) coating at 30% concentration
Number of subjects: 0
Study 23123065 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated specimens)
Number of subjects: 0
Study 21551508 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS 0‐1
Number of subjects: 0
Study 21551508 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS TJC53
Number of subjects: 0
Study 21551508 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS TJC44
Number of subjects: 0
Study 21551508 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS, DAS alternative and DAS28
Number of subjects: 0
Study 21551508 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient percentages with joint damage progression
Number of subjects: 0
Study 18296460 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (selenium 10 mug, zinc 5 mg, vitamin A 0.9 mg, vitamin E 100 mg, vitamin C 50 mg)
Number of subjects: 156
Study 18296460 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (0.1 mg)
Number of subjects: 156
Study 18296460 — intervention group
Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 156
Study 18296460 — intervention group
Group type: COMPARATOR
Intervention: Folinic acid
Number of subjects: 156
Study 18296460 — intervention group
Group type: COMPARATOR
Intervention: Biochemical outcomes
Number of subjects: 156
Study 16516782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome with zero compression heads (160 microm, 180 microm, 200 microm)
Number of subjects: 153
Study 16516782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansatome microkeratome with zero compression heads
Number of subjects: 153
Study 12709801 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem daloxate (300 mg, twice daily for 7 days)
Number of subjects: 452
Study 12709801 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg, twice daily for 7 days)
Number of subjects: 452
Study 12709801 — intervention group
Group type: EXPERIMENTAL
Intervention: Faropenem daloxate
Number of subjects: 452
Study 12709801 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 452
Study 10618328 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes of slow exercise at 2.7 km/h
Number of subjects: 18
Study 10618328 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom limited graded exercise for a mean of 7.4 minutes
Number of subjects: 18
Study 10618328 — intervention group
Group type: EXPERIMENTAL
Intervention: Three minutes of symptom limited fast exercise
Number of subjects: 18
Study 10618328 — intervention group
Group type: COMPARATOR
Intervention: No warm up exercise
Number of subjects: 18
Study 9112443 — intervention group
Group type: EXPERIMENTAL
Intervention: Pion therapy (33-34.5 Gy pi)
Number of subjects: 84
Study 9112443 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon irradiation (60 Gy)
Number of subjects: 84
Study 1287620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 500 mg once daily (at night)
Number of subjects: 189
Study 1287620 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg three times a day
Number of subjects: 189
Study 1287620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF 375 mg twice daily
Number of subjects: 189
Study 1287620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF (375 mg and 500 mg)
Number of subjects: 189
Study 1287620 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 189
Study 1287620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor AF and Cefaclor
Number of subjects: 189
Study 6961477 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 in viscous gel
Number of subjects: 7
Study 6961477 — intervention group
Group type: COMPARATOR
Intervention: placebo gel
Number of subjects: 7
Study 30004247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (training, written menu feedback, printed resources)
Number of subjects: 44
Study 30004247 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study 29874271 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid balance-adjusted creatinine at CVVH initiation
Number of subjects: 107
Study 29874271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate levels
Number of subjects: 107
Study 29874271 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 107
Study 29874271 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted creatinine
Number of subjects: 107
Study 26272450 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral fimasartan (FMS)
Number of subjects: 16
Study 26272450 — intervention group
Group type: COMPARATOR
Intervention: 30 mg intravenous (IV) fimasartan (FMS)
Number of subjects: 16
Study 24629631 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200mg/day) plus CBT
Number of subjects: 74
Study 24629631 — intervention group
Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 74
Study 23027677 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute 1-mg dose of alprazolam
Number of subjects: 0
Study 23027677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18245061 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia consent procedure
Number of subjects: 188
Study 18245061 — intervention group
Group type: COMPARATOR
Intervention: Routine consent condition (control)
Number of subjects: 188
Study 17158250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP (8 cmH(2)O) for 6 h
Number of subjects: 24
Study 17158250 — intervention group
Group type: COMPARATOR
Intervention: Control (nasal mask without CPAP)
Number of subjects: 24
Study 16827766 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg three times a day
Number of subjects: 40
Study 16827766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15000549 — intervention group
Group type: EXPERIMENTAL
Intervention: Turning relative to the room (updated environment)
Number of subjects: 0
Study 15000549 — intervention group
Group type: COMPARATOR
Intervention: Turning relative to the campus (nonupdated environment)
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of randomized trials
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis results
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of meta-analysis
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Limitations of meta-analysis
Number of subjects: 0
Study 10210759 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate effect of treatments
Number of subjects: 0
Study 8896514 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐C7 (anti‐TNF monoclonal antibody)
Number of subjects: 610
Study 8896514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 1812905 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal debonding device
Number of subjects: 15
Study 1812905 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pliers
Number of subjects: 15
Study 6684468 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg X day‐1 for 5 consecutive days
Number of subjects: 12
Study 6684468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1g X day‐1 for 5 consecutive days
Number of subjects: 12
Study 6684468 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive days
Number of subjects: 12
Study 29883839 — intervention group
Group type: COMPARATOR
Intervention: Medical history of asthma or eczema (Control group)
Number of subjects: 876
Study 29883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Children not carrying the IL13-rs20541 variant allele
Number of subjects: 876
Study 29883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Children carrying the IL10 triple variant haplotype
Number of subjects: 876
Study 29883839 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate polymorphisms in IL4 and IL4R
Number of subjects: 876
Study 28210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (5 mg)
Number of subjects: 24
Study 28210808 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol (2.5 mg)
Number of subjects: 24
Study 25907813 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise intervention
Number of subjects: 135
Study 25907813 — intervention group
Group type: COMPARATOR
Intervention: Structured health education control group
Number of subjects: 135
Study 22936524 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA, daily tailored feedback messages (PDA + FB)
Number of subjects: 210
Study 22936524 — intervention group
Group type: COMPARATOR
Intervention: PDA, no-daily feedback
Number of subjects: 210
Study 22936524 — intervention group
Group type: COMPARATOR
Intervention: paper diary (PD), no-daily feedback
Number of subjects: 210
Study 21976939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 80 mg orally, twice a day for four weeks
Number of subjects: 30
Study 21976939 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice a day for four weeks
Number of subjects: 30
Study 18502591 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with BASICS counseling
Number of subjects: 14
Study 15875189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal salmon calcitonin 100 IU day(‐1), 1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D
Number of subjects: 78
Study 15875189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1,000 mg day(‐1) elemental calcium, 400 IU day(‐1) vitamin D)
Number of subjects: 78
Study 12509592 — intervention group
Group type: EXPERIMENTAL
Intervention: FOK plus ImPACT
Number of subjects: 817
Study 12509592 — intervention group
Group type: EXPERIMENTAL
Intervention: FOK plus ImPACT plus boosters
Number of subjects: 817
Study 12509592 — intervention group
Group type: COMPARATOR
Intervention: FOK only
Number of subjects: 817
Study 12509592 — intervention group
Group type: COMPARATOR
Intervention: FOK without boosters
Number of subjects: 817
Study 10759092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and interferon alfa-2b
Number of subjects: 345
Study 10759092 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 345
Study 9017757 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of digit presentation (slow vs fast)
Number of subjects: 0
Study 9017757 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay between stimulus presentation and estimations of time
Number of subjects: 0
Study 9017757 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks (arithmetic and recall)
Number of subjects: 0
Study 2001021 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 6, 9, and 12% (0.83, 1.24, and 1.66 MAC) in O2 alone
Number of subjects: 12
Study 2001021 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 3, 6, and 9% in O2 with 60% N2O
Number of subjects: 12
Study 2001021 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 0.83 and 1.66 MAC after 6 h exposure
Number of subjects: 12
Study 2001021 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia secondary to spontaneous ventilation
Number of subjects: 12
Study 2001021 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic, loud clapping at 1.24 MAC
Number of subjects: 12
Study 6342542 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 30
Study 6342542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31636243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg dexmedetomidine plus local infiltration of 0.2 ml/kg bupivacaine 0.5% (BD)
Number of subjects: 60
Study 31636243 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and normal saline (BO)
Number of subjects: 60
Study 30298411 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP) - two placebo tablets twice daily for 3 weeks
Number of subjects: 40
Study 30298411 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 40
Study 29219945 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS plication of the diaphragm
Number of subjects: 35
Study 29219945 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral simultaneous VATS plication
Number of subjects: 35
Study 25044768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 38
Study 25044768 — intervention group
Group type: COMPARATOR
Intervention: Control (non-diabetic subjects, n=31)
Number of subjects: 38
Study 24386911 — intervention group
Group type: EXPERIMENTAL
Intervention: BD + HDM/SCT
Number of subjects: 56
Study 24386911 — intervention group
Group type: COMPARATOR
Intervention: HDM/SCT alone
Number of subjects: 56
Study 22839300 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive nutrition CD and parenting DVD, along with instructions for optimal resource utilization.
Number of subjects: 150
Study 22839300 — intervention group
Group type: COMPARATOR
Intervention: Generic nutrition and physical activity brochure and a physical activity resource to blind participants to group allocation.
Number of subjects: 150
Study 19686477 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Number of subjects: 80
Study 19686477 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (1.5 ml) with fentanyl (0.3 ml, 15 microg)
Number of subjects: 80
Study 17452505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (4 mg per day)
Number of subjects: 300
Study 17452505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 15054428 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg vitamin C
Number of subjects: 6
Study 15054428 — intervention group
Group type: EXPERIMENTAL
Intervention: 7500 mg vitamin C
Number of subjects: 6
Study 11694610 — intervention group
Group type: COMPARATOR
Intervention: Nutrition counseling training for doctors (20 hours)
Number of subjects: 429
Study 9392913 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 129
Study 9392913 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroids)
Number of subjects: 129
Study 7910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine with 69‐kd membrane protein (CP4)
Number of subjects: 159
Study 7910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine without 69‐kd membrane protein (CP5)
Number of subjects: 159
Study 7910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine combined with diphtheria and tetanus toxoids (CP4DT or CP5DT)
Number of subjects: 159
Study 7910089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine (CP5DT) for 4‐ to 6‐year‐old children
Number of subjects: 159
Study 7910089 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 159
Study 3309829 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefotiam pre-operative antibioprophylaxis
Number of subjects: 115
Study 3309829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cefotiam)
Number of subjects: 115
Study 29872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha 2-a (PEG-IFN α-2a) therapy
Number of subjects: 292
Study 29872876 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 292
Study 26798658 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII + Sig group
Number of subjects: 60
Study 26798658 — intervention group
Group type: COMPARATOR
Intervention: CSII group
Number of subjects: 60
Study 25822572 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (1 mL of methylprednisolone acetate, 40 mg/mL, dissolved in 4 mL of lidocaine hydrochloride, 10 mg/mL)
Number of subjects: 100
Study 25822572 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (1 mL isotonic saline mixed with 4 mL of lidocaine hydrochloride, 10 mg/mL)
Number of subjects: 100
Study 25822572 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid vs Placebo
Number of subjects: 100
Study 24430056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lantoks injections in spastic muscles
Number of subjects: 27
Study 24430056 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (massage, exercise therapy, FTL, pharmacotherapy)
Number of subjects: 27
Study 20003966 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrojejunostomy (GJJ)
Number of subjects: 39
Study 20003966 — intervention group
Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 39
Study 18779281 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 8
Study 18779281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 16377361 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 395
Study 12886239 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN/HU
Number of subjects: 534
Study 12886239 — intervention group
Group type: COMPARATOR
Intervention: HU
Number of subjects: 534
Study 10984564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated-poliovirus vaccine (IPV), administered subcutaneously
Number of subjects: 1025
Study 10984564 — intervention group
Group type: COMPARATOR
Intervention: Trivalent OPV (manufactured in the United States or in Europe)
Number of subjects: 1025
Study 10984564 — intervention group
Group type: COMPARATOR
Intervention: Monovalent type 3 OPV
Number of subjects: 1025
Study 9076288 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter of invitation for a flu vaccine
Number of subjects: 2791
Study 9076288 — intervention group
Group type: EXPERIMENTAL
Intervention: Offer of a free flu vaccine
Number of subjects: 2791
Study 9076288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2791
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontally treated patients with > 5 new DFS% during the 3rd 4-year period (years 9-12)
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with new root caries lesions
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence between 1 and 5 new DFS
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence between 6 and 9 new DFS
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with root caries incidence of 12 or more new DFS
Number of subjects: 27
Study 8436631 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mean number of new DFS
Number of subjects: 27
Study 3784919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 75
Study 3784919 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposom
Number of subjects: 75
Study 3784919 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride
Number of subjects: 75
Study 3784919 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 75
Study 3784919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31064743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer decision-support tools available and used
Number of subjects: 476
Study 31064743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer decision-support tools available and likely to be used
Number of subjects: 476
Study 31064743 — intervention group
Group type: COMPARATOR
Intervention: Practices with cancer decision-support tools
Number of subjects: 476
Study 27816913 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (4 joules/cm², total dose = 40 joules)
Number of subjects: 73
Study 27816913 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 73
Study 25593121 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted catheter-directed thrombolysis
Number of subjects: 48